Akari Therapeutics (AKTX) Share-based Compensation (2012 - 2026)

Akari Therapeutics (AKTX) has 12 years of Share-based Compensation data on file, last reported at $3.2 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 215.27% year-over-year to $3.2 million; the trailing twelve-month figure through Mar 2026 stood at $3.2 million (up 16.7% YoY), and the FY2025 full-year result was $2.9 million, up 28.73% from the prior year.
• Share-based Compensation rose to $3.2 million in Q1 2026, from $2.9 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $3.2 million in Q1 2026 to a low of -$842000.0 in Q4 2023.
• A 5-year average of $921078.4 and a median of $582000.0 in 2024 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation sank 130.74% in 2023 and surged 44400.0% in 2024, its largest moves.
• Tracing AKTX's Share-based Compensation over 5 years: stood at $2.7 million in 2022, then slumped by 130.74% to -$842000.0 in 2023, then surged by 249.17% to $1.3 million in 2024, then soared by 127.95% to $2.9 million in 2025, then increased by 11.77% to $3.2 million in 2026.
• Business Quant data shows AKTX's Share-based Compensation at $3.2 million in Q1 2026, $2.9 million in Q4 2025, and $900000.0 in Q3 2025.